- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
No Biopsy Required For MRI-Detected BI-RADS 2 Lesions
Breast lesions detected by MRI and classified as BI-RADS 2 were shown to not be malignant, and therefore do not need biopsy.
Breast biopsies are unnecessary for breast lesions found by breast MRI and characterized as BI-RADS 2, according to a study published in the journal Clinical Radiology.
Researchers from Austria performed a retrospective single-center study to assess the frequency of malignancies in lesions characterized as benign on breast MRI.
A total of 1,265 patients, mean age 50, were included in the study. All had undergone dynamic contrast-enhanced MRI (1.5 T) of the breast during a six-year period.
The researchers examined the MRI characteristics and frequency of malignancy in 192 of the patients found to have breast lesions classified as BI-RADS 2.
The lesions were either histopathologically verified or subjected to both clinical and imaging follow-up of at least two years (range: two to nine years).
The results showed that no lesions that were classified as BI-RADS 2 were found to be malignant. “Histopathology was available in 67 (34.9%) lesions and revealed benign findings exclusively,” the authors wrote. “The remaining 125 (65.1%) lesions did not exhibit changes during the follow-up period and were, therefore, considered negative for malignancy.”
The researchers concluded that breast biopsies are unnecessary for breast lesions classified as BI-RADS 2, due to the absence of malignancies.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
